BioSpace News Archive

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the second quarter ended June 30, 2023.

SeaStar Medical Holding Corporation, a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and six months ended June 30, 2023 and provides a business update.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the second quarter ended June 30, 2023, and recent business progress.

Today, Resham Ramsay announced the launch of her new consulting firm, MedLark LLC, which will provide quality and regulatory services to medical device, biotechnology, and pharmaceutical companies.

MedAvail Holdings, Inc., an innovative pharmacy technology company, reported financial results for the second quarter ended June 30, 2023.

Vivos Therapeutics, Inc. announced it will reschedule its conference call to review its financial results for the second quarter ended June 30, 2023, previously scheduled for today at 5:00 p.m.

Anbio, a leading provider of innovative diagnostic solutions, proudly presents the Anbio LFA solution, an innovative, easy-to-use, but accurate diagnostic product. Anbio’s LFA solution, or Lateral Flow Assay, is a diagnostic technique for detecting antigens (s) such as viral proteins and cancer biomarkers.

Quantum-Si Incorporated, The Protein Sequencing CompanyTM, announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted non-qualified stock option awards to purchase an aggregate of 739,750 shares of its Class A common stock to 8 new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan.

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today reported financial results for the second quarter of 2023 and provided a business update.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug Administration (FDA) approved HEPZATO KIT.